Loading organizations...
Capacity Bio is a Los Angeles, California-based biotechnology company that develops small molecules, peptides, and nanoparticles targeting mitochondrial biology to treat neurodegenerative disorders, autoimmune conditions, myopathies, and genetic orphan diseases. The company's therapeutic platform focuses on restoring mitochondrial quality control by enhancing the identification of dysfunctional mitochondria, activating mitophagy pathways, and promoting cellular clearance via autophagosomes and lysosomes. To support its preclinical and clinical development programs, the enterprise has raised $35 million in total funding through a Series A financing round co-led by RA Capital Management and Insight Partners, alongside seeding investor Remiges Ventures. The organization also provides an advanced analytical toolkit to characterize mitochondria and is advancing its first-in-class mitophagy agonist toward human clinical trials expected to begin in 2024. Capacity Bio was founded in 2021 by Amy Wang and Taro Inaba.
Capacity Bio has raised $35.0M across 1 funding round.
Capacity Bio has raised $35.0M in total across 1 funding round.
Capacity Bio has raised $35.0M across 1 funding round. Most recently, it raised $35.0M Series A in March 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 1, 2023 | $35M Series A | — | Insight Partners, Cheryl Zimberlin, RA Capital, Remiges Ventures | Announced |
Capacity Bio is a biotechnology company developing a first-in-class mitophagy therapeutic platform and advanced analytical tools to improve mitochondrial quality control.[1][2][4] Founded in 2021 and headquartered in Los Angeles (with early mentions in Palo Alto), it targets mitochondrial dysfunction in diseases like neurodegeneration (Parkinson’s, ALS), muscular disorders (DMD), autoimmune conditions, and genetic orphan indications.[1][2][3] The company has raised $35M in a Series A round from investors including Insight Partners, RA Capital Management, and Remiges Ventures, remaining in pre-clinical development.[1][2]
Capacity Bio serves the healthcare sector by creating small molecules, peptides, and nanoparticles that enhance mitophagy—clearing dysfunctional mitochondria via autophagosomes and lysosomes—to power therapeutic breakthroughs.[1][2] Its pipeline addresses multibillion-dollar markets in neurodegeneration and myopathies, with a unique surface receptor-targeting approach that avoids cellular entry for faster, safer effects.[3]
Capacity Bio was founded in 2021 as a private biotech emerging from academic and scientific advancements in mitochondrial biology.[1][4] Key details on specific founders are not publicly detailed in available sources, but the company's technology stems from discoveries like novel cellular targets for mitochondrial turnover and acidifying nanoparticles for lysosome function, linked to researchers such as Orian Shirihai and Mark Grinstaff, who co-founded related ventures including Enspire Bio.[1]
Remiges Ventures acted as a founding investor, supporting early development of the mitophagy platform.[2] Initial traction came from pre-clinical validation of its mitochondrial characterization toolkit and therapeutics, positioning it quickly for Series A funding amid rising interest in mitochondrial therapies.[1][6] The company relocated or emphasized Los Angeles as its base, aligning with biotech hubs like UCLA's Magnify Incubator ecosystem.[2][3][4]
Capacity Bio stands out in mitochondrial biotech through these key strengths:
Capacity Bio rides the surging trend of mitochondrial medicine, fueled by growing recognition of mitophagy's role in aging-related diseases like neurodegeneration and myopathies, where dysfunctional mitochondria drive pathology.[1][2][3] Timing is ideal amid advances in cellular quality control therapies, with market forces like rising neurodegenerative prevalence (e.g., Parkinson’s, ALS) and biotech funding for platform technologies favoring its pre-clinical stage.[1][6]
It influences the ecosystem by pioneering non-invasive mitophagy inducers, potentially accelerating treatments in a field dominated by gene therapies or antioxidants, and contributes to LA's biotech cluster via incubators like CNSI Magnify.[3][4] This positions it to shape mitochondrial therapeutics, bridging analytics and drugs for faster translation to clinic.
Capacity Bio is poised for IND-enabling studies and Phase 1 trials in neurodegeneration or muscular disorders, leveraging its $35M war chest and investor pedigree to advance its mitophagy platform.[1][2] Trends like AI-driven mitochondrial profiling and combination therapies with immunotherapies will amplify its toolkit's value, while orphan drug incentives could fast-track approvals.[3]
Its influence may evolve from toolkit innovator to category leader in mitophagy, especially if pre-clinical data validates surface-targeting efficacy, tying back to its core mission of restoring mitochondrial health to unlock healthcare breakthroughs.[1][4]
Capacity Bio has raised $35.0M in total across 1 funding round.
Capacity Bio's investors include Insight Partners, Cheryl Zimberlin, RA Capital, Remiges Ventures.
